---
title: "Exagen | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 19.94 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294820656.md"
datetime: "2026-08-04T12:04:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294820656.md)
  - [en](https://longbridge.com/en/news/294820656.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294820656.md)
generator: "portal-rs"
---

# Exagen | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 19.94 M

Revenue: As of FY2026 Q2, the actual value is USD 19.94 M, beating the estimate of USD 17.87 M.

EPS: As of FY2026 Q2, the actual value is USD -0.13, beating the estimate of USD -0.1914.

EBIT: As of FY2026 Q2, the actual value is USD -2.923 M.

### Financial Performance for the Three Months Ended June 30, 2026

#### Gross Margin

Exagen Inc.’s gross margin for the quarter was 61.3%, an increase from 60.4% in the second quarter of 2025. The absolute gross margin was $12,217 thousand, up from $10,395 thousand in 2025.

#### Operating Expenses

Operating expenses totaled $13,939 thousand, an increase from $13,025 thousand in the second quarter of 2025. Selling, general and administrative expenses were $12,513 thousand, and research and development expenses were $1,426 thousand.

#### Operating Loss

Operating loss significantly narrowed to - $1,722 thousand, compared to an operating loss of - $2,630 thousand in the second quarter of 2025.

#### Net Loss

Net loss for the quarter was - $3,196 thousand, a reduction from - $4,439 thousand reported in the second quarter of 2025.

#### Adjusted EBITDA

Adjusted EBITDA improved to a loss of - $114 thousand, compared to a loss of - $1,721 thousand in the second quarter of 2025.

### Financial Performance for the Six Months Ended June 30, 2026

#### Gross Margin

Gross margin for the six-month period was 60.2%, compared to 59.7% in the same period of 2025. The absolute gross margin was $22,422 thousand, up from $19,518 thousand in 2025.

#### Operating Expenses

Total operating expenses for the six months were $27,558 thousand, an increase from $25,513 thousand in the prior year period. Selling, general and administrative expenses were $24,579 thousand, and research and development expenses were $2,979 thousand.

#### Operating Loss

Operating loss for the six months was - $5,136 thousand, an improvement from - $5,995 thousand in the corresponding period of 2025.

#### Net Loss

Net loss for the six months ended June 30, 2026, was - $7,163 thousand, compared to - $8,191 thousand in the same period of 2025.

#### Adjusted EBITDA

Adjusted EBITDA for the six-month period was a loss of - $2,274 thousand, improving from a loss of - $4,229 thousand in the prior year.

### Cash and Cash Equivalents

Exagen Inc. ended the quarter with $24,588 thousand in cash and cash equivalents as of June 30, 2026, compared to $30,033 thousand as of June 30, 2025.

### Operational Metrics

AVISE CTD test volume grew by 11% compared to the second quarter of 2025. The AVISE CTD trailing twelve-month average selling price (ASP) expanded to $446 per test, an increase of $18 or 4% compared to the second quarter of 2025.

### 2026 Guidance

Exagen Inc. increased its full-year 2026 revenue guidance to a range of $72 million to $75 million. This updated guidance is higher than the previous projection of $70 million to $73 million.

### Related Stocks

- [XGN.US](https://longbridge.com/en/quote/XGN.US.md)

## Related News & Research

- [Exagen Q2 revenue beats on test volume growth; raises 2026 outlook](https://longbridge.com/en/news/294822149.md)
- [A Peek at Exagen's Future Earnings](https://longbridge.com/en/news/278426924.md)
- [Maintaining a Buy: Conservative Guidance but Solid Demand and Pipeline Support Long-Term Upside](https://longbridge.com/en/news/278587819.md)
- [Exagen Earnings Report: Q4 Overview](https://longbridge.com/en/news/278551881.md)
- [Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven](https://longbridge.com/en/news/286124993.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**